Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System.
Milutinovic S, Jancic P, Jokic V, Petrovic M, Dumic I, Rodriguez AM, Tanasijevic N, Begosh-Mayne D, Stanojevic D, Escarcega RO, Lopez-Mattei J, Cao X.
Milutinovic S, et al. Among authors: rodriguez am.
Pharmaceuticals (Basel). 2024 Oct 15;17(10):1372. doi: 10.3390/ph17101372.
Pharmaceuticals (Basel). 2024.
PMID: 39459012
Free PMC article.